Bulletin
Investor Alert

New York Markets Close in:

Teva Pharmaceutical Industries Ltd. ADR

NYS: TEVA

GO
/marketstate/country/us

Countdown to close

 --Real time quotes

Feb 3, 2023, 3:41 p.m.

/zigman2/quotes/205657894/composite

$

10.74

Change

+0.03 +0.28%

Volume

Volume 5.09m

Real time quotes

/zigman2/quotes/205657894/composite

Previous close

$ 10.71

$ 10.74

Change

+0.03 +0.28%

Day low

Day high

$10.61

$10.80

Open

52 week low

52 week high

$6.78

$11.45

Open

Company Description

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates...

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Valuation

P/E Current

29.68

P/E Ratio (without extraordinary items)

22.05

Price to Sales Ratio

0.58

Price to Book Ratio

0.93

Price to Cash Flow Ratio

3.78

Enterprise Value to EBITDA

7.51

Enterprise Value to Sales

2.16

Total Debt to Enterprise Value

0.74

Efficiency

Revenue/Employee

1,363,661.00

Income Per Employee

35,884.00

Receivables Turnover

3.55

Total Asset Turnover

0.33

Liquidity

Current Ratio

1.14

Quick Ratio

0.79

Cash Ratio

0.20

Profitability

Gross Margin

47.10

Operating Margin

19.36

Pretax Margin

4.15

Net Margin

2.63

Return on Assets

0.87

Return on Equity

4.20

Return on Total Capital

8.67

Return on Invested Capital

1.30

Capital Structure

Total Debt to Total Equity

229.31

Total Debt to Total Capital

69.63

Total Debt to Total Assets

49.44

Long-Term Debt to Equity

214.37

Long-Term Debt to Total Capital

65.10

Officers and Executives

Name Age Officer Since Title
Dr. Eric Drapé 59 2013 Executive Vice President-Global Operations
Mr. Eli Kalif 48 2019 Chief Financial Officer & Executive Vice President
Dr. Eric A. Hughes - 2022 Chief Medical Officer, Executive VP-Global R&D
Mr. John Nason - 2015 President-Biologics Operations

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/10/2018 Bridger Management LLC
Director
250,000   Acquisition at $19.32 per share. 4,830,000
05/09/2018 Bridger Management LLC
Director
500,000   Acquisition at $19.21 per share. 9,605,000
/news/latest/company/us/teva

MarketWatch News on TEVA

  1. Apple Is Not the Economy. Why the Fed’s More Bullish Than Tech.

    6:33 a.m. Today

    - Barron's Online

  2. Teva names former Sandoz chief Richard Francis as new CEO

    7:16 a.m. Nov. 21, 2022

    - Steve Gelsi

  3. Teva Pharmaceutical names pharma exec Richard Francis and president and CEO

    7:05 a.m. Nov. 21, 2022

    - Steve Gelsi

  4. New Teva CEO Richard Francis was CEO of Sandoz and Biogen exec

    7:05 a.m. Nov. 21, 2022

    - Steve Gelsi

  5. Teva CEO Kåre Schultz to retire on Dec. 31

    7:05 a.m. Nov. 21, 2022

    - Steve Gelsi

  6. Teva Pharmaceutical downgraded to underweight from neutral at J.P. Morgan

    6:45 a.m. Nov. 14, 2022

    - Tomi Kilgore

  7. Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says

    11:28 a.m. Nov. 3, 2022

    - Barron's Online

  8. Teva Pharmaceutical upgraded to buy from neutral at BofA Securities

    8:44 a.m. Aug. 5, 2022

    - Tomi Kilgore

  9. $4.4 Billion Opioid Settlement Gives Teva Stock a Boost

    2:32 a.m. July 28, 2022

    - Barron's Online

  10. Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement

    5:14 a.m. July 27, 2022

    - Barron's Online

  11. Teva to pay $75 mln over 15 years to settle opioid claims from W. Va., plus pay $8 mln in legal fees

    8:46 a.m. May 25, 2022

    - Steve Gelsi

  12. Teva settlement with W. Va. also includes $27 mln worth of generic Narcan over 10 years

    8:46 a.m. May 25, 2022

    - Steve Gelsi

  13. W. Va. says Teva opioid agreement consistent with previously announced settlements

    8:46 a.m. May 25, 2022

    - Steve Gelsi

  14. Loading more headlines...
/news/nonmarketwatch/company/us/teva

Other News on TEVA

  1. Humira Faces Competition From First U.S. Copycat

    6:23 a.m. Feb. 1, 2023

    - The Wall Street Journal Interactive Edition

  2. DEA Pressed ADHD-Drug Makers About Impact of Telehealth Firms on Surging Demand

    10:20 a.m. Dec. 31, 2022

    - The Wall Street Journal Interactive Edition

  3. World’s Top-Selling Drug Going Off Patent Means Big Bucks for Middlemen

    3:21 a.m. Nov. 28, 2022

    - The Wall Street Journal Interactive Edition

  4. Teva Pharmaceutical Names Richard Francis as CEO

    2:32 a.m. Nov. 22, 2022

    - The Wall Street Journal Interactive Edition

  5. Opioid reversal agent naloxone approvable for OTC use – FDA

    1:37 p.m. Nov. 15, 2022

    - Seeking Alpha

  6. Top 5 3rd Quarter Trades of DSC Advisors, L.P.

    8:00 a.m. Nov. 15, 2022

    - GuruFocus.com

  7. Teva slips as JPMorgan downgrades on growth concerns

    9:01 a.m. Nov. 14, 2022

    - Seeking Alpha

  8. BECK MACK & OLIVER LLC Buys 2, Sells 3 in 3rd Quarter

    6:00 p.m. Nov. 10, 2022

    - GuruFocus.com

  9. Teva Pharmaceutical to Replace CEO Kare Schultz

    3:24 p.m. Nov. 3, 2022

    - The Wall Street Journal Interactive Edition

  10. 10-Q: TEVA PHARMACEUTICAL INDUSTRIES LTD

    3:22 p.m. Nov. 3, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  11. Loading more headlines...

At a Glance

Teva Pharmaceutical Industries Ltd.

124 Dvora HaNevi'a Street

Tel Aviv, TA 6944020

Phone

972 39148213

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$51.19B

Net Income

$1.35B

Employees

37,537

/news/pressrelease/company/us/teva

Press Releases on TEVA

  1. Teva Pharmaceutical TEVA Investment Analysis

    10:49 a.m. Jan. 23, 2023

    - Stock Traders Daily

  2. Teva Pharmaceutical TEVA Technical Data

    8:43 p.m. Jan. 13, 2023

    - Stock Traders Daily

  3. Teva Pharmaceutical TEVA Proactive Strategies

    5:58 a.m. Jan. 4, 2023

    - Stock Traders Daily

  4. Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference

    4:30 p.m. Jan. 3, 2023

    - BusinessWire - BZX

  5. Teva Pharmaceutical TEVA Trading Signals

    2:17 p.m. Dec. 25, 2022

    - Stock Traders Daily

  6. Teva Pharmaceutical TEVA Technical Pivots with Risk Controls

    11:56 p.m. Dec. 15, 2022

    - Stock Traders Daily

  7. Teva Pharmaceutical TEVA Investment Report

    9:43 a.m. Dec. 6, 2022

    - Stock Traders Daily

  8. EFV, KESG: Big ETF Outflows

    10:50 a.m. Dec. 2, 2022

    - MarketNewsVideo.com

  9. Teva Pharmaceutical (TEVA) Trading Report

    6:20 p.m. Nov. 26, 2022

    - Stock Traders Daily

  10. Teva Finalizes Nationwide Opioid Settlement Terms

    8:30 a.m. Nov. 22, 2022

    - BusinessWire - BZX

  11. Teva Announces Appointment of Richard Francis as President and CEO

    7:00 a.m. Nov. 21, 2022

    - BusinessWire - BZX

  12. Learn to Evaluate Teva Pharmaceutical (TEVA) using the Charts

    3:09 a.m. Nov. 17, 2022

    - Stock Traders Daily

  13. Loading more headlines...
Link to MarketWatch's Slice.